Pharmaceutical Regulatory Authority GUIDELINE ON APPLICATION FOR REGISTRATION OF UNREGISTERED VETERINARY MEDICINES ALREADY ON THE ZAMBIAN MARKET

Similar documents
GUIDELINES FOR REGISTRATION OF MEDICINES IN THE GAMBIA

APPLICATION FOR MARKETING AUTHORIZATION OF A PHARMACEUTICAL PRODUCT FOR HUMAN USE IN UGANDA

GUIDELINES FOR REGISTRATION OF IMPORTERS AND FOR THE IMPORTATION OF MEDICINES AND RELATED PRODUCTS

REPUBLIC OF MAURITIUS APPLICATION FOR REGISTRATION OF A DRUG

GUIDELINES FOR MEDICINAL PRODUCT REGISTRATION

GUIDELINE FOR REGISTRATION OF MEDICINES

to The Uganda Gazette No. 18 Volume CVII dated 28th March, 2014 Printed by UPPC, Entebbe, by Order of the Government No. 29.

GLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE

GUIDELINES ON APPLICATION FOR REGISTRATION OF VETERINARY MEDICINES

Regulation Regarding the Packaging and Labeling of Medicinal Products for Human Use

Guidelines for application for Registration of Medicinal Products 2006(DRA)

REGULATION (EC) No 542/95

MINISTRY OF HEALTH AND SOCIAL SERVICES

GUIDELINES FOR INTRODUCING A LOCALLY MANUFACTURED NEW PHARMACEUTICAL PRODUCT ON THE UGANDA MARKET

G/TBT/N/MYS/8 Proposal to enforce the Control of Drugs and Cosmetics Regulations 1984 on veterinary medicinal products.

MINISTRY OF PUBLIC HEALTH GENERAL SECRETARIAT MADAGASCAR DRUG S AGENCY EDÑ Ì ÑFG EFÌGD EÌD

CHECKLIST FOR VARIATIONS APPLICATIONS FOR MEDICINES

Table of Contents Section 1: Section 2: Section 3: Section 4: Section 5: Section 6: Section 7:

GUIDELINES FOR SUBMISION OF POST- APPROVAL VARIATION MEDICINE APPLICATIONS

GUIDELINES FOR MEDICAL DEVICES REGISTRATION

1.1 Product(s) registered for sale in Singapore by the Health Sciences Authority (HSA) will be given priority.

Medicine Variations Guideline

CGMP Requirements for Investigational Products

Registration Application form for Vaccines (To be submitted in duplicate electronic copies)

GUIDELINES ON THE IMPORT AND EXPORT OF REGISTERED MEDICINES

Internationally harmonised requirements for batch certification

DEVELOPMENT PHARMACEUTICS AND PROCESS VALIDATION

A GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999

GUIDELINES ON FORMAT AND CONTENT OF LABELS FOR MEDICINAL PRODUCTS

Product Literature Standard

Agencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio Madrid España (Reference Member State)

Medicines Variations Guideline

Medicines Control Authority of Zimbabwe

Republic of the Philippines Department of Health OFFICE OF THE SECRETARY M a n i l a

APPLICATION FOR VARIATION TO A MARKETING AUTHORISATION

Guideline on the label design for Injections (Draft for Comments)

MANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS

GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE IA AND TYPE IB NOTIFICATIONS July 2003

Pharmaceutical product technical requirements and the Interagency pharmaceutical product questionnaire

Guidelines for Pharmaceutical Equivalence Requirements

General concepts in the Ph. Eur.: theory and rationale

GUIDANCE FOR INDUSTRY ON FIXED DOSE COMBINATIONS (FDCs)

Investigational Product (Pharmaceutical) Management. Sudhakar Bangera MD, MMedSc Program Director, CDSA

TYPE 1 - NEW PRODUCT APPLICATION FORM:

FOOD AND DRUGS AUTHORITY

Kingdom of Swaziland Ministry of Health. Guidelines on Import Procedures for Medicines

DRUG REGULATORY PROCEDURES IN TANZANIA: A GLIMPSE

L 159/24 EN Official Journal of the European Union. COMMISSION REGULATION (EC) No 1085/2003. of 3 June 2003

1. Checklist for Grant of permission to manufacture/import of Bulk Drug already approved in the country

GLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE

WHO guidelines on variations to a prequalified product

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE:

ZAMBIA MEDICINES REGULATORY AUTHORITY APPLICATION FOR MARKETING AUTHORISATION OF A MEDICINE FOR HUMAN USE

Public Assessment Report Scientific discussion. Lueva (Desogestrel) SE/H/1135/01/DC

EN Official Journal of the European Union. (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 1084/2003.

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

ANMAT Order No 5260/2008

Brief Introduction of Aburaihan Company Organization Policy Organization Chart Qualified Human Resource Production Department Engineering Department

Product Permission Document (PPD) of Typhoid Polysaccharide Vaccine I.P. (Brand Name Bio-Typh TM )

5. Changes to a CEP or to a confirmation of API-prequalification document 106

Phase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017

DRUGS DIRECTORATE GUIDELINES PREPARATION OF DRUG IDENTIFICATION NUMBER SUBMISSIONS

Medical Device Regulatory Framework 9 SEPTEMBER 2015 FUNDISA CONFERENCE JANE ROGERS

Public Assessment Report Scientific discussion. Celecoxib Pfizer (celecoxib) SE/H/1076/01-02/DC

Documentation requirements for an initial consultation

Guide to Fees for Veterinary Products

Guide to EU Clinical Trial Application Form

MODULE 2.3 QUALITY OVERALL SUMMARY PRODUCT DOSSIER (QOS PD)

Institute of Pharmaceutical Technololgy and Biopharmacy University of Pécs

Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review

WHOPAR. SCIENTIFIC DISCUSSION

Guideline on the Regulation of Therapeutic Products in New Zealand

DIRECTORATE: AGRICULTURAL INPUTS CONTROL PHARMACEUTICAL AND ANALYTICAL GUIDELINES STOCK REMEDIES

How to use the defective product report to notify a quality defect to European Medicines Agency

Public Assessment Report Scientific discussion. Amitriptylin Abcur (amitriptyline hydrochloride) SE/H/1643/01-03/MR

Ensuring Quality Pharmacy Compounding: Implications for Pharmaceutics Education

Product Permission Document (PPD) of Botulinum Toxin Type A for Injection Ph.Eur Purified Neurotoxin Complex

Agencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio Madrid España (Reference Member State)

SCIENTIFIC DISCUSSION

(Information) INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION

GUIDELINES ON THE PHARMACEUTICAL & ANALYTICAL DATA REQUIRED FOR REGISTRATION OF STOCK REMEDIES IN SOUTH AFRICA

Introduction of OTC switch in China. Han Qing Regulatory Affairs of One China OTC J&J Oct

GUIDANCE ON PHARMACEUTICAL PRODUCTS REGISTRATION IN PALESTINE

DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Unit 208 Assist with the manufacture and assembly of medicinal products

INFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES COMMISSION

GUIDANCE ON VARIATIONS TO A PREQUALIFIED DOSSIER

Bringing ideas to life. Full-service pharmaceutical, nutraceutical and cosmetic contract manufacturing

The GCC Guidelines for Stability Testing of Drug Substances and Pharmaceutical Products EDITION TWO 1428 H 2007 G

ZAMBIA MEDICINES REGULATORY AUTHORITY APPLICATION FOR MARKETING AUTHORISATION OF A MEDICINE FOR HUMAN USE

MEDICINES CONTROL COUNCIL

Medicines Control Authority Of Zimbabwe

ANNEX V ASEAN GUIDELINES ON STABILITY STUDY AND SHELF-LIFE OF HEALTH SUPPLEMENTS

GUIDELINES ON THE STABILITY DATA REQUIRED FOR REGISTRATION OF STOCK REMEDIES IN SOUTH AFRICA

DRUG REGISTRATION REGULATION

Our vision APL

COMMON TECHNICAL REQUIREMENTS ACTR. one vision one identity one community

HEALTH DEPARTMENT. On the margin, a seal bearing the national symbol and the words United Mexican States Health Department.

Materials Management Traceability, CEPs and managing non-conforming sites

Drug Products, Labeling, and Packaging

Transcription:

GUIDELINE ON APPLICATION FOR REGISTRATION OF UNREGISTERED VETERINARY MEDICINES ALREADY ON THE ZAMBIAN MARKET ABBREVIATIONS µg Microgram API Active Pharmaceutical Ingredient ATC Anatomic Therapeutic Chemical classification BP British Pharmacopoeia cgmp current Good Manufacturing Practices e.c Enteric coated f.c Film coated FDC Fixed dose combination FP Finished Product GMP Good Manufacturing Practice GS General Sale i.m Intramuscular i.v Intravenous INN International Non-proprietary Name IP International Pharmacopoeia IU International Unit JP Japanese Pharmacopoeia M.R Modified Release mg Milligram ml Millilitre OIE Office International des Epizooties Page 1 of 9

P Pharmacy Ph. Eur European Pharmacopoeia POM Prescription Only Medicines PRA Pharmaceutical Regulatory Authority s.c Sugar coated SPC Summary of Product Characteristics SR Sustained release USP United States Pharmacopoeia VM Veterinary medicines VMP Veterinary Medicinal Product. WHO World Health Organization DEFINITIONS OF TERMS For the purposes of these guidelines, the following definitions shall apply: Active pharmaceutical ingredient (API) means a substance or compound that is intended to be used in the manufacture of a pharmaceutical product as a therapeutically active compound (ingredient). Authority means the Pharmaceutical Regulatory Authority established under Section 4 of the Pharmaceutical Act No 14 of 2004. ATC Classification means the Anatomical Therapeutic Chemical Classification system as per description given on www.whocc.no/atcvet Composition composition in relation to a medicinal product means the ingredients of which it consists, proportions, degree of strength, quality and purity in which those ingredients are contained. Container means a bottle, jar, box, packet, sachet or other receptacle which contains or is to contain in it, not being a capsule or other article in which the product is or is to be administered or consumed, and where any such receptacle is or is to be contained in another receptacle, includes the former but does not include the latter receptacle. Container labeling Means all information that appears on any part of a container, including that on any outer packaging such as a carton. Page 2 of 9

Veterinary Medicines, Medicinal or Pharmaceutical product Means any substance or mixture of substances manufactured sold or represented for use in: (a) The diagnosis, treatment, mitigation or prevention of a disease, disorder, abnormal physical or mental state, or the symptoms thereof, in an animal; (b) Restoring, correcting or beneficial modification of organic or mental functions in an animal; (c) Disinfections of premises in which Medicines are manufactured, prepared or kept, animal hospitals or clinics and equipment; (d) Articles intended for use as a component of any articles specified in clause (a), (b) or (c); but does not include medical devices or their components, parts or accessories. Excipient means any component of a finished dosage form which has no therapeutic value Finished product means a product that has undergone all stages of production, including packaging in its final container and labelling Formulation means the composition of a dosage form, including the characteristics of its raw materials and the operations required to process it. General sale Medicines (GS) means any medicines whose use does not need the direction or prescription by a Veterinary surgeon or dentist. Generic products means products that are pharmaceutical equivalents or alternatives to innovator or reference products and which are intended to be therapeutically equivalent and can therefore be used interchangeably with the innovator or reference product. Immediate release dosage form means a dosage form that is intended to release the entire active ingredient on administration with no enhanced, delayed or extended release effect. Impurities include by-product of synthesis arising from side reactions products in starting materials etc., residual solvents and reagents, trace elements arising from other sources and products of degradation Innovator (or pioneer) pharmaceutical product means a pharmaceutical product which was first authorized for marketing (normally as a patented product) on the basis of documentation of quality, safety and efficacy. Label means any tag, brand, mark, pictorial or other descriptive matter, written, printed, stencilled, marked, embossed or impressed on or attached to a container of any Medicines Manufacture means production, quality control, release and packaging of a product. Manufacturer means a firm that is engaged in the manufacture of products Page 3 of 9

Pharmacopoeia includes but not limited current edition of the British Pharmacopoeia, European Pharmacopoeia, United States Pharmacopoeia, International Pharmacopoeia and Japanese Pharmacopoeia. Shelf Life means the combination of physical, chemical, biological and microbiological test requirements that determine whether a Medicines product is suitable for release at the time of its manufacture WHO-type certificate means a certificate of pharmaceutical product of the type defined in the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce OIE means the World Organisation for Animal Health. Meat means animal tissue used as food. Proprietary name means the (trade or brand) name, which is unique to a particular medicine and by which it is generally identified (and by which it is registered in the country of manufacture). Approved/ INN / generic name in relation to a medicine mean the internationally recognized nonproprietary name of such a Medicines. Dosage form means the form in which the medicine is presented, e.g. solution, suspension, eye drops, emulsion, ointment, suppository, tablet, capsule, etc. For injections, the type of presentation (e.g. vial, ampoule, dental cartridge, etc), and the type of content (e.g. powder for reconstitution, solution, suspension, oily solution, etc.) shall also be stated. Description of the product means a full visual description of the medicine including colour, size, shape and other relevant features, e.g. black and red gelatin capsule with marks Ampro, Green uncoated bolus with word ALBENDAZOL embossed on one side etc. Commercial Presentation means the final product pack as it will be presented in the market (e.g. 10 ampoules of 2ml each, 10 blister packs of 10capsules each, etc.) Page 4 of 9

1. Introduction: The Pharmaceutical Act (No. 14) of 2004 requires that veterinary medicinal products intended to be marketed in Zambia meet acceptable standards of quality, safety and efficacy and at the same time be assessed to have been manufactured in facilities which comply with current Good Manufacturing Practices (cgmp). One of the means for ensuring that a veterinary medicinal product meets the required standards of quality, safety and efficacy is by conducting product specific pre-marketing assessments to determine whether the product should be registered. These guidelines have been prepared to provide information to applicants who intend to register veterinary medicinal products which are already on the Zambian Market. This document is intended to provide guidance to applicants on how to complete each part of the application form and the procedure for submitting the application. 2.0 Submitting Applications A separate application is required for each product. Products differing in active ingredient(s), strength, dosage forms, package size (preparations for injection only) or manufactured at different sites are considered to be different products and hence require separate applications. Applications shall be made by submitting a duly completed application form in a prescribed format. The application shall be made both in hard and electronic copies (word format) and this application should be accompanied by: i). ii). iii). iv). A non-refundable registration fee; Proof of registration of the product in the country of origin (such as; WHO-type Certificate of a Pharmaceutical Product specifically addressed to Zambia, Registration Certificate, Free Sale Certificate or an equivalent document); Package insert, if information is not part of the label; Two (2) samples of the smallest commercial pack(s) with the respective batch certificate of analysis. All documents shall be addressed to the Director General, Pharmaceutical Regulatory Authority, Tuleteka Road, Off Makishi Plot No.6903 Rhodes Park, P.O. Box 31890, LUSAKA. 3.0 Completing the Application Form The application form should be completed in a legible font in English. Where the space may not be enough extra pages can be attached. Page 5 of 9

3.1 Details of Applicant The Application maybe made by: - A manufacturer; - Patent holder/owner of the formulation; - Person responsible for placing the product on the market with power of Attorney from or contract with the manufacturer or owner of the formulation All the details required in this section should be provided and where the applicant has power of attorney or contract with manufacturer or owner of formulations the relevant documentation should be submitted with the application. Type of applicant should be indicated by way of ticking in the appropriate box on the application form. 3.2 Details of the Distributor Every applicant should have a local distributor who is resident in Zambia. A Distributor is a person(s) registered to conduct business in Zambia with legal authorization to take full responsibility for the product on behalf of the applicant. Letter of appointment as distributor from the applicant should be submitted. The name, physical and postal address, telephone number, fax number and e- mail address should be provided. 3.3 Manufacturer(s), Site(s) for the Finished Veterinary Medicinal Product The following information relating to the manufacturer shall be provided by the applicant: The name, physical address, telephone number, fax number, and e- mail address of the manufacturer shall be provided. Where different activities of manufacture of a given product are carried out at different manufacturing sites, the above particulars shall be provided for each site and the activity carried out at the particular site shall be stated. 3.4 Name of Product and Dosage Form The following details of the veterinary medicine shall be submitted: - Proprietary name - Approved INN / generic name - Dosage form Page 6 of 9

3.5 Description of the Veterinary Medicinal Product A full description of the product including; physical characteristics, consistency of the product, shape, size, colour, odour, taste, type of tablet (i.e. s.c, f.c, e.c, SR etc). Liquids should be clearly stated if it is emulsion, elixir, suspension etc. (e.g. Green uncoated bolus with word ALBENDAZOL embossed on one side) 3.6 Active Pharmaceutical Ingredient(s) The following details of the active pharmaceutical ingredient(s) shall be submitted: - Name - Strength - Anatomic-therapeutic classification system (ATC) code. Refer to WHO collaborating centre for drug methodology statistics for current codes (www.whocc.no/atcvet/) 3.7 Therapeutic indications A full description of all indications the product is intended for, including target species should be provided. 3.8 Directions for Use A full description of method of use should be provided and should include dosage, route of administration, dilution rates, frequency and duration of treatment for each indication and species. 3.9 Contraindications/ Drug interactions A full description of situations, species and breeds in which the product is contraindicated should be provided. A full description of all possible drug interactions should be provided 3.10 Warnings/Precautions/Overdosage A full description of all warnings or precautions including those that need to be taken by persons administering/handling the product should be given. Concise symptoms of overdosage and possible management should be provided. 3.11 Side effects A full description of common side effects should be given. Page 7 of 9

3.12 Withdrawal Periods Details of withdrawal periods should be provided in all food producing animals clearly indicating the time for each type of animal product (i.e. eggs, meat, milk etc). 3.13 Storage Conditions Clear instructions on the storage of the product should be provided and should include specific storage temperature and those related to light and humidity. 3.14 Container- Closure System and Administration Devices A full description of the nature of material construction of the container- closure system should be provided. The details should include; size, shape, colour and details of desiccant, rubber stoppers, seal, devoid filler when present. Specification and full description of administrative devices should be provided where applicable. 3.15 Package Sizes/ Presentation Details of all packages sizes intended for the market should be provided (e.g. 100ml vial, 2 x 10 boluses). 3.16 Shelf Life Shelf life should be provided in months. 3.17 Method of sale/ Category of Distribution The method of distribution should be stated as one of the following: - Prescription only medicine (POM) - Pharmacy (P) - General sale Medicine (GS) 3.18 Composition The approved INN /generic name (s) and the chemical name (s) of the substances (active and inactive) shall be given, and in the absence of a chemical name, the chemical nature of the substance shall be described. Trade names shall not be used. Quantities shall be given in terms of the dosage unit, e.g. mg/ tablet, g/ml, etc. Specifications or reference text shall be precisely stated, e.g. BP (Vet) 2006 page 200. The reason for inclusion of each inactive ingredient (excipient) in the formulation shall be stated. Any raw materials used, although not present in final dosage form, shall also be stated. Page 8 of 9

3.19 Any Other Information Details of the product not described above that might be useful in the registration of the product should be provided. This could include any safety updates, status of registration in other countries etc. 3.20 Declaration by an Applicant Each application form shall be duly signed by an authorised person who should be a regulatory affairs person, company pharmacist or quality control manager. The name, qualification, position in the company, signature and date on which that person signed should be submitted. Page 9 of 9